Table 3.
Medical treatments and surgical procedures in the immigrant and native-born IBD population in Spain.
| Immigrants | Natives | p -value | |
|---|---|---|---|
| N (%) | |||
| Endoscopic treatment | 24/1517 (1.6) | 425/10663 (3.9) | <0.001 |
| Immunosuppresants | 1006/1835 (54.8) | 6126/11651 (52.6) | 0.082 |
| Biologics | 643/1766 (36.4) | 3469/11651 (29.8) | <0.001 |
| AntiTNF | 637 (34.2) | 3405 (29.2) | 0.038 |
| Vedolizumab | 2 (0.1) | 41 (2.5) | |
| Ustekinumab | - | 19 (0.16) | |
| Others | 2 (0.1) | 4 (0.03) | |
| IBD-related surgery | 389/1763 (22.1) | 2742/11651 (23.5) | 0.184 |
| Abdominal surgery for CD* | 276 (29.4) | 2253 (34.5) | 0.002 |
| Total proctocolectomy for UC** | 37 (3.5) | 240 (3.4) | 1 |
| Perianal surgery | 154 (8.3) | 1372 (11.8) | 0.184 |
Percentages are calculated based on patients with available data.
*
Percentage calculated on CD patients.
**
Percentage calculated on UC patients.